

IN THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Claims 1-25 (canceled).

Claim 26 (currently amended): A method for inducing CTL that specifically recognize a complex of an HLA-A26 antigen and a peptide as set forth in any one of SEQ ID NOs: 2, 8 and 9, which comprises contacting peripheral blood mononuclear cells ~~derived~~ from an HLA-A26 positive subject with ~~the~~ said peptide.

Claim 27 (previously presented): The method according to Claim 26, wherein the subject is positive for WT1.

Claim 28 (previously presented): The method according to Claim 26, wherein the peptide is SEQ ID NO: 2.

Claim 29 (previously presented): The method according to Claim 26, wherein the peptide is SEQ ID NO: 8.

Claim 30 (previously presented): The method according to Claim 26, wherein the peptide is SEQ ID NO: 9.

Claim 31 (new): The method according to Claim 26, wherein said peripheral blood mononuclear cells are isolated from said subjected and contacted with said peptide *ex vivo*.

Claim 32 (new): The method according to Claim 27, wherein said peripheral blood mononuclear cells are isolated from said subjected and contacted with said peptide *ex vivo*.

Claim 33 (new): The method according to Claim 28, wherein said peripheral blood mononuclear cells are isolated from said subjected and contacted with said peptide *ex vivo*.

Claim 34 (new): The method according to Claim 29, wherein said peripheral blood mononuclear cells are isolated from said subjected and contacted with said peptide *ex vivo*.

Claim 35 (new): The method according to Claim 30, wherein said peripheral blood mononuclear cells are isolated from said subjected and contacted with said peptide *ex vivo*.